Evidence for progressional changes in the human malignant glioma line U-343 MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor

Three cell samples in different passages of the line U-343 MGa, derived from a human malignant glioma biopsy, gave rise to clones with different amounts of platelet-derived growth factor (PDGF)-like activity secreted to extracellular medium, and of 125I-labeled PDGF binding. Sixteen clones were completely karyotyped with the G-banding technique. The unique markers 1p-q+, 16p- found in all clones, as well as in the parallel uncloned line, U-343 MG, provided evidence of their common origin. The deduced early, possibly partly primary, deviations had the formula 44, XY, 1p-q+, -14, 16p-, -22, where loss of one chromosome 22 is in accordance with previous reports on early chromosomal deviations in gliomas. Two clones, the hypodiploid 26L and 5H, represented early progressional changes. The other clones followed two patterns of late progressional changes, probably starting from the karyotype of 5H, with additional markers and doubling of the stemlines. In late progressional line I 12q+ and in II +7 were the most characteristic findings. Northern blot analysis using complementary DNA clones for the A and B chains of PDGF showed that both PDGF chains were expressed in 26L and 5H indicating that activation of the PDGF genes could have been an early event in the development of this glioma. Clones with late progression pattern II had been subjected to the highest selective pressure in vitro, and they secreted the highest amount of PDGF-like activity to the extracellular medium. Among them were the most rapidly and tightly growing cells and some clones with high 125I-labeled epidermal growth factor binding. Possibly these findings reflect progressional changes including defective regulation of the growth factor/growth factor receptor genes, selected for in vitro, without involving gross rearrangements or amplifications of the genes. The possible significance of extra chromosomes 7, with the PDGF A chain and epidermal growth factor receptor genes, and of the 12q+ marker, located near the gamma interferon gene is discussed.

Frequent expression of growth factors for mesenchymal cells in human mammary carcinoma cell lines

The expression of growth factors for mesenchymal cells was investigated in 10 different human mammary carcinoma cell lines. Expression of mRNA for platelet-derived growth factor (PDGF) A-chain, PDGF B-chain, transforming growth factor-alpha, and insulin-like growth factor II were found in eight, nine, five, and two of the cell lines, respectively. The production of PDGF-like growth factors by the mammary carcinoma cell lines was investigated in detail. PDGF receptor competing activity and mitogenic activity, which could be neutralized by PDGF antibodies, were found in the conditioned medium of almost all the cell lines. A PDGF-like growth factor was partially purified from the conditioned medium of one of the cell lines, MCF7. A Mr 31,000 component, which was reduced to Mr 17,000, was furthermore precipitated by a PDGF antiserum from the conditioned medium of metabolically labeled MCF7 cells. These results indicate that growth factors for mesenchymal cells are frequently expressed in human mammary carcinoma cell lines. This is of interest in relation to the fact that mammary carcinoma tumors often contain a high proportion of proliferating connective tissue cells.

Induction of platelet-derived growth factor gene expression during megakaryoblastic and monocytic differentiation of human leukemia cell lines

Platelet-derived growth factor (PDGF) is one of the most important polypeptide growth factors in human serum. It is composed of two polypeptide chains linked by disulfide bonds. The B-chain is encoded by the c-sis proto-oncogene, which is expressed in several malignant and non-malignant cells including K562 cells differentiating towards megakaryoblasts. Expression of the A-chain has been reported to occur in human solid tumor cell lines independently of c-sis expression. We report here the non-coordinate expression of the A- and B-chains in human leukemia cell lines. The PDGF-A and B-chain (c-sis) RNA expression as well as secretion of PDGF polypeptides are induced in the K562 cell line upon induction of megakaryoblastic differentiation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) whereas erythroid differentiation induced with sodium butyrate is accompanied by c-sis expression only. Simultaneously with megakaryoblastic differentiation the RNA level for another platelet protein, the transforming growth factor-beta was also increased, but in a complex manner. The promyelocytic leukemia cell line HL-60 does not express PDGF-A RNA, whereas the promonocytic cell line U937 does. Preferential induction of the A-chain RNA is obtained in both cell lines after treatment with TPA which causes monocytic differentiation. PDGF-A expression in HL-60 cells is also observed after treatment with the tumor necrosis factor-alpha but granulocytic differentiation of HL-60 cells induced with dimethyl sulfoxide or the granulocyte colony-stimulating factor is not associated with PDGF gene expression.

Expression of multiple growth factors in a human lung cancer cell line

U-1810, a human large-cell lung cancer line, was found to express a PDGF-like growth factor. 35S-cysteine labelling and immunoprecipitation revealed the synthesis and secretion of a 31-kDa PDGF-like protein. Serum-free conditioned medium contained PDGF-receptor-competing and mitogenic activity when tested on human fibroblasts. Whereas the receptor-competing activity was fully neutralized by anti-PDGF antibodies, the mitogenic activity was only partially affected. We therefore probed U-1810 mRNA with a panel of growth-factor DNA clones. We found expression of the genes for PDGF A- and B-chains, TGF-alpha, TGF-beta and IGF-II but not EGF or IGF-I. U-1810 cells lacked specific binding sites for PDGF but showed specific binding of EGF and expressed EGF-receptor transcripts. Thus, U-1810 is an example of a human tumor cell line that expresses multiple growth factor genes; in the intact tumor the corresponding growth factors may operate in autocrine stimulation of the tumor cells as well as in paracrine growth reactions (i.e. stroma recruitment).

Cultured human endothelial cells express platelet-derived growth factor A chain

Four principal cell types involved in the pathophysiologic response of the vessel wall--endothelial cells, smooth muscle cells, platelets, and monocyte/macrophages--secrete platelet-derived growth factor-like (PDGF-like) mitogenic activities. Extensive structural data on these activities exist only for the mitogen produced by platelets, which is a 30-kd dimeric protein composed of structurally related A and B polypeptide chains encoded by different genes. It was previously demonstrated that normal cultured endothelial cells transcribe mRNA encoding the B chain of PDGF from the c-sis gene. Here several new structural features of the mitogen produced by cultured vascular endothelial cells are shown. Hybridization analysis of RNA from normal cultured human umbilical vein endothelial (HUVE) cells revealed that they contain three PDGF A chain transcript species. These RNA species comigrated with and appeared to have the same relative abundance as the three RNA species previously identified in RNA from two human tumor cell lines. A chain transcripts were not identified in RNA from a strain of bovine aortic endothelial cells or in human dermal fibroblasts. The A chain transcripts in HUVE had the same relative abundance as the B chain transcripts. Immunoprecipitation of metabolically labeled endothelial conditioned medium with anti-PDGF antiserum revealed a 31-kd species which was split by reduction and alkylation into two species of 16.5 and 17 kd. Thus, endothelial cells secrete a dimeric mitogen antigenically related to PDGF, with a structure identical to previously isolated PDGF A-chain homodimer. These findings are consistent with the possibility that secretion of PDGF by human endothelial cells may be regulated independently of B-chain expression.

Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor

Normal human melanocytes and five human melanoma cell lines were analyzed for production of platelet-derived growth factor (PDGF)-like activity. Three of the melanoma cell lines released an activity that inhibited binding of 125I-labeled PDGF to human foreskin fibroblasts and stimulated [3H]thymidine incorporation in such cells. These activities were inhibited by the addition of anti-PDGF antibodies. All three factor-producing cell lines were derived from the same patient--one originated from the primary tumor (WM 115), and two were from individual lymph-node metastases (WM 239A and WM 266-4). The factor produced by WM 266-4 cells was characterized biochemically in detail. Immunoprecipitated, the metabolically labeled factor migrated in NaDod-SO4/gel electrophoresis as a homogeneous Mr 31,000 species, which under reducing conditions was resolved into two species of Mr 16,500 and Mr 17,000, implying a dimeric structure of the molecule. The factor was purified to homogeneity. Analysis by reverse-phase high-pressure liquid chromatography of reduced and alkylated factor revealed an elution pattern identical to that of PDGF A chains. Thus, the native molecule appears to be a homodimer of PDGF A chains. Blot-hybridization analysis of poly(A)+ RNA from the cell lines with 32P-labeled PDGF A chain and B chain (SIS product) cDNA probes revealed a relative abundance of B chain transcripts in the cell line originating from the primary tumor tissue only but expression of A chain in all three cell lines. We conclude that the two structural genes encoding each of the subunit chains of PDGF can be expressed in human melanoma cells and that the two genes can be independently expressed in such cells.

Rat skeletal myoblasts and arterial smooth muscle cells express the gene for the A chain but not the gene for the B chain (c-sis) of platelet-derived growth factor (PDGF) and produce a PDGF-like protein

It is shown here that the myogenic cell line L6J1, primary skeletal myoblasts, and primary adult arterial smooth muscle cells express the gene for the A chain but not the gene for the B chain (c-sis) of platelet-derived growth factor (PDGF). It is further demonstrated that conditioned media from L6J1 cultures contain material that (i) competes with 125I-labeled PDGF for binding to human fibroblasts, (ii) is specifically precipitated by antibodies against PDGF, and (iii) has a relative molecular mass comparable to that of PDGF and, after reduction, its constituent subunit chains. The secretion of PDGF-receptor-competing activity was at a maximum in exponentially growing cultures but remained at a high level also after the cells had become confluent, stopped dividing, and fused to form multinucleate myotubes. Similarly, it was previously demonstrated that adult rat arterial smooth muscle cells in primary culture produce a mitogenic protein with immunological and structural properties similar to PDGF. In accordance with these findings, it was recently shown that secretion of PDGF-like mitogens by a number of human tumor cell lines correlates with expression of the gene for the A chain rather than the B chain of PDGF. The results suggest that production of homodimers of PDGF A chains may stimulate proliferation of skeletal myoblasts and arterial smooth muscle cells in an autocrine or paracrine manner. This could fulfill important functions during myogenesis in the embryo as well as in tissue repair and atherogenesis in the adult.

Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin

Simian sarcoma virus, an acutely transforming primate retrovirus with capacity to induce gliomas and sarcomas in experimental animals, has acquired its transforming properties by transducing the cellular gene sequences that encode one of the constituent chains of platelet-derived growth factor. Suramin, a drug used in the treatment of trypanosomiasis and onchocerciasis, has previously been reported to inhibit the interaction of platelet-derived growth factor with its cell surface receptor. We show here that suramin efficiently reverts the simian sarcoma virus-induced transformed phenotype in human and rat fibroblasts and propose that this is due to neutralization of an externalized v-sis product. Moreover, we show that suramin inhibits the action of a broad spectrum of growth factors.

Growth factors induce early pre-replicative changes in senescent human fibroblasts

As human fibroblasts in culture senesce their response to platelet-derived growth factor (PDGF) becomes attenuated. To clarify at which level such cells are blocked in the pre-replicative part of the cell cycle, we have analysed PDGF-induced pre-replicative events in senescent (phase III) cultures. We found that phase III cells retain a normal number of PDGF receptors and that these are functional with regard to PDGF-induced receptor autophosphorylation. Phase III cells also respond to PDGF by rapid actin reorganization and increased levels of c-fos and c-myc mRNA, similar to growth-arrested phase II fibroblasts. However, the expression of the nuclear antigen K-67, which in phase II cell is induced in S-phase and continues to be expressed throughout the cell cycle, is not induced in phase III cells in response to PDGF. We conclude that phase III human fibroblasts, although blocked with regard to proliferation, still retain a functional growth factor receptor system, and display early responses when exposed to growth factors, such as changes in the cytoskeleton and the expression of proto-oncogenes.

The phenotypic characteristics of simian sarcoma virus-transformed human fibroblasts suggest that the v-sis gene product acts solely as a PDGF receptor agonist in cell transformation

Previous studies have indicated that the oncogene v-sis of simian sarcoma virus (SSV) encodes a growth factor that is structurally and functionally similar to platelet-derived growth factor (PDGF). In the present investigation we have analysed the phenotypic characteristics of human foreskin fibroblasts transformed by SSV. It was found that the PDGF receptors were extensively down-regulated. This finding is consistent with a high, local, extracellular concentration of a PDGF-like factor, synthesized by the transformed cell. The receptors were up-regulated by suramin, a drug that is known to dissociate PDGF and the v-sis product from the PDGF receptors. A cell-associated v-sis product of mol. wt 24,000 was identified by immunoprecipitation with PDGF antibodies; release of this component was induced by a high concentration of exogenous PDGF, indicating that a fraction of the product is associated with the PDGF receptors. SSV was not found to be an immortalizing virus; when serially passaged, SSV-transformed cells had essentially the same life-span as their non-transformed counterparts. Moreover, SSV did not induce growth in soft agar beyond the level afforded by exogenously added PDGF. Thus, the present study favors the notion that SSV transformation is mediated by a growth factor that mimics PDGF but has no further cellular effects.

cDNA sequence and chromosomal localization of human platelet-derived growth factor A-chain and its expression in tumour cell lines

The amino-acid sequence of the precursor of the human tumour cell line-derived platelet-derived growth factor (PDGF) A-chain has been deduced from complementary DNA clones and the gene localized to chromosome 7. The protein shows extensive homology to the PDGF B-chain precursor. Expression of the PDGF A-chain gene is independent of that of the PDGF B-chain in a number of human tumour cell lines, and secretion of a PDGF-like growth factor of relative molecular mass 31,000 correlates with expression of A- but not B-chain messenger RNA.

A human osteosarcoma cell line secretes a growth factor structurally related to a homodimer of PDGF A-chains

Platelet-derived growth factor (PDGF), as purified from fresh human platelets, is a protein of relative molecular mass (Mr) 30,000 composed of two disulphide-linked subunit chains of similar size, named A and B (ref. 1). The dimer structure of PDGRF seems to be important for its biological effects, as reduction irreversibly inactivates the factor; it is not known, however, whether PDGF exists as a heterodimer or as a mixture of homodimers. Amino-acid sequence analysis has revealed that the A- and B-chains of human PDGF are related to each other, and that the B-chain is almost identical to part of the v-sis gene product of simian sarcoma virus (SSV). There is experimental evidence that a PDGF-like protein is indeed operational in SSV-induced transformation and the biologically active v-sis product is probably structurally similar to a putative dimer of PDGF B-chains. PDGF-like growth factors and/or a 4.2-kilobase (kb) c-sis transcript are present in several transformed mammalian cell lines and in certain nontransformed cells; cloned c-sis complementary DNA from human T cells transformed with human T-lymphotropic virus (HTLV) or from human endothelial cells contains the coding sequence for a putative PDGF B-chain precursor, but apparently lacks PDGF A-chain sequences. We have previously partially purified and characterized a PDGF-like growth factor from U-2 OS cells (osteosarcoma-derived growth factor, ODGF) and shown that this factor has structural, functional and immunological characteristics in common with PDGF. We describe here a procedure for the preparation of homogeneous ODGF, and provide evidence that this factor, which binds to the PDGF receptor, has a structure similar to a homodimer of PDGF A-chains.

Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus

A clue to the molecular mechanism of neoplastic transformation was provided by the finding of a near identity in amino-acid sequence between the platelet-derived growth factor (PDGF) B-chain and a region in the transforming protein, p28sis, of simian sarcoma virus (SSV), an agent that causes sarcomas and gliomas in experimental animals. This finding infers a direct link between the molecular biology of normal mitogenesis and oncogenesis since it suggests that the transforming activity of SSV is caused by a growth factor. Although PDGF agonist activity has been isolated from conditioned medium of SSV-transformed cells, it is not clear whether infection of responsive cells by SSV leads solely to autocrine stimulation of growth by a secreted PDGF-like factor or whether other, possibly intracellular, activities of p28sis or its processed products contribute to the transformation. To distinguish between these possibilities, we have studied the effect of anti-PDGF antibodies on acute SSV-transformation, and report here that these antibodies inhibit both proliferation and SSV-induced morphological changes in human diploid fibroblasts.

Cell-type-specific pattern of myc protooncogene expression in developing human embryos

The expression of viral oncogenes in cells transformed by acutely transforming retroviruses profoundly alters proliferation and differentiation in the target cell, suggesting that the cellular homologues of the viral oncogenes, the protooncogenes, have a role in normal cell proliferation and differentiation. To investigate the possible developmental role of protooncogenes in human embryogenesis, we have determined the spatial distribution of myc gene transcripts in early human embryos by using in situ hybridization of a labeled myc exon to thin sections. The results indicate a stage- and cell-type-specific regulation of c-myc gene expression in primarily epithelial cells of late first trimester embryos. Furthermore, the data suggest that the linkage between c-myc gene expression and cellular proliferation holds for only a restricted set of embryonic cells.

Expression of the c-sis gene and secretion of a platelet-derived growth factor-like protein by simian virus 40-transformed BHK cells

SV40-transformed BHK cells were shown to express two transcripts, of 3.5 kb and 2.0 kb, that hybridised to a human c-sis probe. Antibodies directed against human PDGF specifically recognized a 31 kDa protein in SV40/BHK cell conditioned medium, which upon reduction was split into 16 kDa species. Unfractionated conditioned medium and one of two growth factors isolated from SV40/BHK cells competed with 125I-PDGF for binding to its receptor. The present communication thus provides compelling evidence that an SV40/BHK cell-derived growth factor is a hamster equivalent to human PDGF.

Effects of metabolic inhibitors on the distribution of 45-Ca in subcellular fractions from pancreatic islets

It is well established that intracellular calcium buffering is of vital importance for the regulation of insulin release. The metabolic inhibitors, cyanide and N-ethylmaleimide, both decreased the 45-Ca content of a mitochondrial fraction isolated from glucose-stimulated pancreatic islets. We suggest that the main mechanism behind this decrease is an impaired uptake of the isotope, since cyanide had no effect on the 45-Ca wash-out from the mitochondrial fraction of preloaded islets.

Coexpression of the sis and myc proto-oncogenes in developing human placenta suggests autocrine control of trophoblast growth

First trimester human placentas actively express the sis proto-oncogene, the structural gene for the B chain of platelet-derived growth factor (PDGF). Using the in situ hybridization technique, the 4.2 kb c-sis transcript has been localized to the cytotrophoblastic component, especially the highly proliferative and invasive cytotrophoblastic shell, paralleling the distribution of c-myc transcripts in early placenta. Explants of first trimester placenta release significant levels of PDGF-like activity into the medium under apparent developmental control. Moreover, cultured trophoblasts display abundant high-affinity PDGF receptors and respond to exogenous authentic PDGF by an activation of the c-myc gene and DNA synthesis. The developing human placenta may therefore represent a case of autocrine growth regulation in a normal tissue, in which cells bearing receptors for a growth factor can also synthesize and respond to that factor.

Platelet-derived growth factor: mechanism of action and relation to oncogenes

Recent studies of platelet-derived growth factor (PDGF) have revealed several structural and functional similarities between this growth factor or components linked to its mechanism of action and certain oncogene products: PDGF itself has a structural homology with the transforming protein of simian sarcoma virus, the PDGF receptor has a functional homology (tyrosine kinase activity) with a family of oncogene products, and PDGF induces the expression of the cellular counterparts of myc and fos. In addition, several tumour cell lines have been found to produce PDGF-like growth factors, which may cause autocrine stimulation of growth. We interpret these findings as indicating that regulatory components along the PDGF-dependent mitogenic pathway may have oncogenic properties if they are inappropriately expressed or activated.

Coexpression of a PDGF-like growth factor and PDGF receptors in a human osteosarcoma cell line: implications for autocrine receptor activation

The expression of both a PDGF-like growth factor and functional PDGF receptors within a clonal human osteosarcoma cell line (U-2 OS Cl 6) is demonstrated. These molecules are able to interact and induce tyrosine-specific phosphorylation and early actin reorganization in the osteosarcoma cells, effects similar to those that PDGF induces in normal responsive cells. Furthermore, immunoprecipitation with an antiserum against phosphotyrosine revealed that a 115 kd protein was constitutively phosphorylated in U-2 OS Cl 6 cells. A phosphorylated protein of similar apparent molecular weight has been found in human fibroblasts, but only after stimulation with PDGF. These data indicate that the PDGF-receptor-dependent pathway is constitutively activated in this cell line. Extracellularly added PDGF antibodies did not, however, affect the transformed properties or growth rate of U-2 OS Cl 6 cells in vitro. This indicates that autocrine PDGF receptor activation may be insignificant for maintaining the transformed state of this tumor cell line, or that autocrine receptor activation occurs in a compartment where it is inaccessible to extracellularly added antibodies.

Growth factor-induced proliferation of human fibroblasts in serum-free culture depends on cell density and extracellular calcium concentration

Human neonatal skin fibroblasts plated sparsely in MCDB 105 traversed a complete cell cycle in the absence of serum or serum-derived proteins. Addition of pure PDGF did not significantly increase entrance into S phase as revealed by 3H-thymidine labeling index or clonal growth on palladium islands. In subphysiologic Ca2+ concentrations or in the presence of a calmodulin inhibitor, W7, proliferation in the absence of growth factors ceased and PDGF became mitogenic. In contrast, confluent fibroblast cultures were stimulated by PDGF in physiologic Ca2+ concentrations. This was also the case with sparse adult skin fibroblast cultures while a fetal strain entered S in the absence of PDGF even in low extracellular Ca2+ concentrations. EGF gave similar results as PDGF in all experiments performed. This proposes a similar role for the two growth factors in the cell cycle. However, a difference in the mechanisms of action of PDGF and EGF is indicated by the fact that PDGF and EGF were additive at optimal concentrations when maximal growth response by a single growth factor was restricted by a subphysiologic extracellular Ca2+ concentration.

Synthesis of a PDGF-like growth factor in human glioma and sarcoma cells suggests the expression of the cellular homologue to the transforming protein of simian sarcoma virus

Several human normal and neoplastic cell lines were screened for production of PDGF receptor competing activity. Conditioned medium from two sarcomas and one glioma blocked 125I-PDGF binding to human foreskin fibroblasts in a dose-dependent manner. In each case this effect was abolished when the conditioned medium was pretreated with PDGF-antiserum, indicating that the receptor competing activity was immunologically related to PDGF. Direct evidence for de novo synthesis of a PDGF-like component in the cultures was afforded by 35S-cysteine labeling of the three cell lines, followed by immunoprecipitation with PDGF antiserum. This resulted in the specific precipitation of a 31,000 molecular weight labeled protein, which upon reduction was split into two polypeptides of molecular weights 17,000 and 16,500. The significance of these findings in view of the recently discovered structure homology between PDGF and the transforming gene product of simian sarcoma virus, p28sis, is discussed.

Calcium and pancreatic beta-cell function. 12. Modification of 45Ca fluxes by excess of K+

Glucose stimulation of insulin release is supposed to result from depolarization of the pancreatic beta-cells with subsequent influx of Ca2+. Isolated islets from non-inbred ob/ob-mice were employed for elucidating whether the glucose effects on the beta-cell handling of Ca2+ could be simulated by the depolarization evoked by excess of K+. Addition of 25 mM K+ was as effective as 20 mM glucose in stimulating the intracellular uptake of 45Ca. In both instances the additional amounts of incorporated 45Ca appeared in the mitochondria and the secretory granules. When analysing the washout pattern for 45Ca it was evident that the effects of raising K+ differed from those evoked by glucose. Whereas glucose inhibited 45Ca efflux during perifusion with Ca2+-deficient medium the addition of K+ resulted in a slight stimulation. Furthermore, the 45Ca incorporated in response to K+ was more readily mobilised.

Ca2+ transport in pancreatic beta-cells during glucose stimulation of insulin secretion

The role of Ca2+ in the regulation of insulin secretion was evaluated using beta-cell-rich pancreatic islets isolated from ob/ob-mice. The glucose stimulation of the secretory activity is supposed to result from accumulation of Ca2+ in the submembrane cytoplasmic space. It is likely that this process reflects the balance between increased entry of Ca2+ into the beta-cells and an enhanced sequestration of Ca2+ in the organelle sinks. The proposed model can explain the cAMP potentiation of glucose-stimulated insulin release with suppression of the mitochondrial Ca2+ uptake. Furthermore, differences in the Ca2+ buffering capacity of the secretory granules may account for other characteristic features of glucose-stimulated insulin release, in particular its biphasic nature and sensitivity to suppression on withdrawal of nutrients.